Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 19/20 | 0.60 |
| ▸ | CTSS | P25774 | 8/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877426 | 0.82 | CTSK (0.68) | CTSKCTSSKCNH2CTSBCTSL | |
| SCHEMBL3873029 | 0.80 | CTSK (0.57) | CTSKCTSSKCNH2CTSBCTSL | |
| SCHEMBL3875703 | 0.79 | CTSK (0.69) | CTSKCTSSKCNH2CTSBCTSL | |
| SCHEMBL3873554 | 0.78 | CTSK (0.67) | CTSKCTSSKCNH2CTSBCTSL | |
| SCHEMBL3874455 | 0.77 | CTSK (0.70) | CTSKCTSSKCNH2CTSBCTSL | |
| SCHEMBL4444344 | 0.75 | CTSK (1.00) | CTSKCTSSKCNH2CTSBCTSL | |
| SCHEMBL3876247 | 0.75 | CTSK (0.54) | CTSKCTSSKCNH2CTSBCTSL | |
| SCHEMBL4592830 | 0.73 | CTSK (0.50) | CTSKCTSSKCNH2CTSBCTSL | |
| SCHEMBL8277368 | 0.73 | CTSK (0.76) | CTSKCTSSKCNH2CTSBCTSL | |
| SCHEMBL3873916 | 0.72 | CTSK (0.65) | CTSKCTSSKCNH2CTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928842-B1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | ORGANON NV (NL) | 2009-11-18 | — | — | EP | claimed |
| EP-1928842-A1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2008-06-11 | — | — | EP | claimed |
| US-7326715-B2 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2008-02-05 | — | — | US | claimed |
| US-20070111992-A1 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | claimed |
| WO-2007039470-A1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | claimed |
| EP-1928842-B1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | ORGANON NV (NL) | 2009-11-18 | — | — | EP | disclosed |
| EP-1928842-A1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2008-06-11 | — | — | EP | disclosed |
| US-7326715-B2 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2008-02-05 | — | — | US | disclosed |
| US-20070111992-A1 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039470-A1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111992-A1 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | CTSK, CTSS, CTSF | CTSK 1/4885CTSS 2/4885KCNH2 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.